Quarterly report pursuant to Section 13 or 15(d)

Sponsored Research and License Agreements (Details)

v3.3.0.814
Sponsored Research and License Agreements (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2015
Aug. 31, 2015
Mar. 31, 2015
Feb. 28, 2015
Sep. 30, 2015
Sep. 30, 2015
bristol-Myers Squibb Company            
Collaborations            
Noncreditable and nonrefundable upfront payment by BMS     $ 30,000,000      
Deferred revenue related to upfront payment $ 18,300,000     $ 30,000,000 $ 18,300,000 $ 18,300,000
Revenue recognized         4,800,000 11,700,000
bristol-Myers Squibb Company | Research Activities            
Collaborations            
Revenue recognized         163,000 619,000
bristol-Myers Squibb Company | Minimum            
Collaborations            
Contingent payments by BMS       $ 309,000,000    
Aclaris Therapeutics            
Collaborations            
Upfront fee received 8,000,000          
Contingent payments by BMS   $ 80,000,000        
Revenue recognized         8,000,000 8,000,000
Collaborative Arrangement            
Collaborations            
Maximum amount of contingent payments receivable 533,600,000       533,600,000 533,600,000
Collaborative Arrangement | Specified Development Events            
Collaborations            
Maximum amount of contingent payments receivable 150,500,000       150,500,000 150,500,000
Collaborative Arrangement | Specified Regulatory Events            
Collaborations            
Maximum amount of contingent payments receivable 345,600,000       345,600,000 345,600,000
Collaborative Arrangement | Specified Product Launch Events            
Collaborations            
Maximum amount of contingent payments receivable $ 37,500,000       $ 37,500,000 $ 37,500,000